6/28/23, 1:15 AM DAPA-CKD (post-hoc analysis) Pathway Feedback Search Clinical Topics Home Studies DAPA CKD (post-hoc analysis) DAPA CKD (post-hoc analysis) Disease Chronic kidney disease Trial question What is the role of dapagliflozin in patients with CKD? Study design Multi-center Double blinded RCT Population Characteristics of study participants 33.0% female N = 4292 67.0% male 4292 patients (1419 female, 2873 male) Inclusion criteria: patients with CKD with and without anemia Key exclusion criteria: T1DM, polycystic kidney disease, lupus nephritis, or antineutrophil cytoplasmic antibody-associated vasculitis Interventions N=2147 dapagliflozin (at a dose of 10 mg/day) N=2145 placebo (matching placebo daily) Primary outcome https://web.pathway.md/studies/recdBri1niwtd7DYo 1/2 6/28/23, 1:15 AM DAPA-CKD (post-hoc analysis) Pathway Significant increase in improvement in hematocrit during follow-up (2% vs. -0.3%; AD 2.3%, 95% CI 2.1 to 2.5) Secondary outcomes Borderline significant increase in correction of anemia in patients with anemia (53.3% vs. 29.4%; HR 2.29, 95% CI 1.96 to 2.68) Borderline significant decrease in incident anemia in patients without anemia (10.4% vs. 23.7%; HR 0.39, 95% CI 0.31 to 0.48) Borderline significant increase in the percentage of patients achieving 3% improvement in hematocrit (69% vs. 37%; HR 2.57, 95% CI 2.35 to 2.81) Safety outcomes No significant difference in adverse events. Significant difference in anemia-related adverse events (2.2% vs. 3.8%). Conclusion In patients with CKD with and without anemia, dapagliflozin was superior to placebo with respect to improvement in hematocrit during follow-up. Reference Akihiko Koshino, M.D., Meir Schechter et al. Dapagliflozin and Anemia in Patients with Chronic Kidney Disease. NEJM Evid. 2023;2(6). Open reference URL https://web.pathway.md/studies/recdBri1niwtd7DYo 2/2